95% CI 0.8, 2.4)
North Texas Research Forum 2025 Files Download Full Text (492 KB) Division North Texas Hospital Medical City Arlington Specialty Obstetrics & Gynecology Document Type Poster Publication Date 2025 Keywords non-arteriticanterior ischemic optic neuropathy, semaglutide, type 2 diabetes, weight loss, GLP-1RA Disciplines Internal Medicine | Medicine and Health Sciences | Obstetrics and Gynecology Abstract Background: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-RA), was introduced and approved by the United States Food and Drug Administration (FDA) for the management of type 2 diabetes in 2017
In September 2025, the agency had already issued a Warning Letter to Hims objecting to false or misleading marketing claims on its website related to compounded GLP-1 injections
How do I know how many units to inject
In one study 11 conducted on rats in 2020, ALCAR reduced the expressions of inflammation factors in serum, aortic, and heart tissues. The study authors concluded that ALCAR can inhibit the expressions of inflammatory factors and antioxidation to suppress the development of atherosclerosis by adjusting blood lipid in the myocardium of AS (atherosclerosis) rats. With such a broad range of benefits, a well-formulated, high quality ALCAR supplement may offer a smart way to improve fat loss, energy production and derive certain cognitive benefits
Tirzepatide is the current "king" of approved weight loss drugs, but dual glucagon agonists (like Mazdutide) are theoretically capable of surpassing it by burning more calories
